Thomas Steyer’s Neurogene NGNE Stock Holding History

Thomas Steyer’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-2,405	Closed	-$451K	–	90
2014 Q2	$451K	Sell	2,405 -95	-4%	-$18.3K	0.01%	97
2014 Q1	$637K	Buy	+2,500	New	+$643K	0.01%	87

Other funds holding NGNE

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Franklin Resources

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 39.77% 1-Year Est. Return

Thomas Steyer's NGNE Position: Q3 2014 in Review

Thomas Steyer sold out of Neurogene (NGNE) in Q3 2014, closing a stake of 2,405 shares — an estimated $451K sold.

Thomas Steyer first reported a position in NGNE in Q1 2014 and held it in 2 quarters. The position peaked at $637K in Q1 2014. 22 funds tracked by Wall St. Rank hold NGNE as of Q3 2014.

Thomas Steyer reported no remaining Neurogene position as of Q3 2014 after selling out during the quarter.
Thomas Steyer sold 2,405 Neurogene shares in Q3 2014, an estimated $451K.
Thomas Steyer first reported a position in Neurogene in Q1 2014 and held it in 2 quarters.
Thomas Steyer's Neurogene position peaked at $637K in Q1 2014.
22 funds tracked by Wall St. Rank held Neurogene as of Q3 2014.

Based on Farallon Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.